2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow ferumoxtran-10: new trials by email Literature Review of ferumoxtran-10 trials Research Report on ferumoxtran-10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer fludeoxyglucose F 18, positron emission tomography, computed tomography - Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 384 | 2007-09-01 | 2019-07-23 |
| Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide MRI contrast agent Combidex (ferumoxtran-10) - Uterine Neoplasms, Cervix Neoplasms | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 61 | 2004-04-01 | 2022-10-07 |
Uterine Cervical Neoplasms (2) · Endometrial Neoplasms (1) · Prostatic Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Neoplasms (1)
National Cancer Institute (NCI) (1) · University Health Network, Toronto (1)
Canada (2) · Japan (1) · South Korea (1) · United States (1)
Michael Milosevic, MD (1) · Mostafa Atri (1)
U10CA027469 (1), U10CA180868 (1)